Luminus Management LLC Lucid Diagnostics Inc. Transaction History

Luminus Management LLC

$150 Million
Q2 2024

A detailed history of Luminus Management LLC transactions in Lucid Diagnostics Inc. stock. As of the latest transaction made, Luminus Management LLC holds 725,825 shares of LUCD stock, worth $682,275. This represents 0.4% of its overall portfolio holdings.

Number of Shares

725,825

Previous 717,657 1.14%

Holding current value

$682,275

Previous $581,000 2.41%

% of portfolio

0.4%

Previous 0.27%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.67 - $1.04 $5,472 - $8,494	8,168 Added 1.14%	725,825 $595,000
Q1 2024 May 15, 2024	SELL	$0.81 - $1.52 $45,027 - $84,495	-55,589 Reduced 7.19%	717,657 $581,000
Q4 2023 Feb 15, 2024	SELL	$1.16 - $1.54 $118,150 - $156,855	-101,854 Reduced 11.64%	773,246 $1.09 Million
Q3 2023 Nov 14, 2023	SELL	$1.17 - $1.65 $3,835 - $5,408	-3,278 Reduced 0.37%	875,100 $1.02 Million
Q2 2023 Aug 14, 2023	BUY	$1.28 - $1.78 $29,539 - $41,078	23,078 Added 2.7%	878,378 $1.22 Million
Q1 2023 May 15, 2023	BUY	$1.17 - $1.77 $35,451 - $53,631	30,300 Added 3.67%	855,300 $1.2 Million
Q4 2022 Feb 14, 2023	SELL	$1.21 - $2.27 $26,211 - $49,172	-21,662 Reduced 2.56%	825,000 $1.12 Million
Q3 2022 Nov 14, 2022	SELL	$1.53 - $3.45 $41,527 - $93,639	-27,142 Reduced 3.11%	846,662 $1.3 Million
Q2 2022 Aug 15, 2022	BUY	$1.73 - $3.44 $204,697 - $407,027	118,322 Added 15.66%	873,804 $1.98 Million
Q1 2022 May 13, 2022	SELL	$2.85 - $5.24 $1.43 Million - $2.63 Million	-502,582 Reduced 39.95%	755,482 $2.54 Million
Q4 2021 Feb 15, 2022	BUY	$4.87 - $11.76 $6.13 Million - $14.8 Million	1,258,064 New	1,258,064 $6.76 Million

Others Institutions Holding LUCD

# of Institutions

Shares Held

2.05M

Call Options Held

Put Options Held

View Full List

About Lucid Diagnostics Inc.

Ticker LUCD
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 38,568,500
Market Cap $36.3M
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarc...

More about LUCD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Luminus Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Luminus Management LLC with notifications on news.

Account

Luminus Management LLC Lucid Diagnostics Inc. Transaction History